21 | LipopolysaccharidesIBA
01/2021
-
02/2002 |
6 | Dinoprostone (PGE2)FDA Link
01/2018
-
09/2003 |
6 | Oxygen (Dioxygen)IBA
10/2015
-
01/2002 |
5 | Nitric Oxide (Nitrogen Monoxide)FDA Link
01/2016
-
02/2002 |
5 | Prostaglandins EIBA
06/2010
-
07/2002 |
4 | Nitric Oxide Synthase (NO Synthase)IBA
01/2016
-
02/2002 |
4 | ProstaglandinsIBA
10/2015
-
07/2004 |
3 | EndotoxinsIBA
01/2021
-
02/2002 |
3 | CytokinesIBA
01/2019
-
06/2009 |
3 | PyrogensIBA
01/2018
-
04/2005 |
3 | LeptinIBA
11/2017
-
03/2007 |
3 | 4- (5- (4- chlorophenyl)- 3- (trifluoromethyl)- 1H- pyrazol- 1- yl)benzenesulfonamideIBA
10/2015
-
08/2009 |
3 | Prostaglandin-Endoperoxide Synthases (Cyclooxygenase)IBA
08/2009
-
11/2005 |
3 | Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
06/2009
-
12/2004 |
3 | Serotonin (5 Hydroxytryptamine)IBA
05/2005
-
12/2002 |
3 | Carbon MonoxideIBA
05/2003
-
02/2002 |
3 | Heme Oxygenase (Decyclizing) (Heme Oxygenase)IBA
05/2003
-
02/2002 |
2 | NAD (NADH)IBA
01/2021
-
09/2014 |
2 | Pharmaceutical PreparationsIBA
11/2018
-
06/2010 |
2 | AcidsIBA
01/2017
-
09/2002 |
2 | NG-Nitroarginine Methyl Ester (L-NAME)IBA
01/2016
-
04/2004 |
2 | AntipyreticsIBA
01/2016
-
02/2002 |
2 | NitratesIBA
01/2016
-
02/2002 |
2 | SC 560IBA
10/2015
-
08/2009 |
2 | Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)IBA
10/2015
-
02/2013 |
2 | disodium (R,R)- 5- (2- ((2- (3- chlorophenyl)- 2- hydroxyethyl)- amino)propyl)- 1,3- benzodioxole- 2,3- dicarboxylateIBA
09/2014
-
06/2010 |
2 | capsazepineIBA
05/2011
-
12/2004 |
2 | resiniferatoxinIBA
05/2011
-
12/2004 |
2 | Protein Isoforms (Isoforms)IBA
08/2009
-
02/2002 |
2 | EnzymesIBA
10/2006
-
09/2005 |
2 | Proteins (Proteins, Gene)FDA Link
09/2005
-
07/2002 |
2 | Lactic Acid (Lactate)FDA LinkGeneric
10/2003
-
09/2002 |
2 | adenosine-3',5'-cyclic phosphorothioateIBA
12/2002
-
07/2002 |
2 | Cyclic GMP-Dependent Protein Kinases (Protein Kinase G)IBA
12/2002
-
07/2002 |
2 | Cyclic AMP-Dependent Protein Kinases (cAMP-Dependent Protein Kinase)IBA
12/2002
-
07/2002 |
2 | Arginine (L-Arginine)FDA Link
12/2002
-
02/2002 |
1 | Indicators and Reagents (Reagents)IBA
01/2021 |
1 | OvalbuminIBA
01/2021 |
1 | LeukotrienesIBA
01/2021 |
1 | Cytotoxins (Cytolysins)IBA
08/2019 |
1 | piperlongumineIBA
08/2019 |
1 | 3- (4- t- butylphenyl)- N- (2,3- dihydrobenzo(b)(1,4)dioxin- 6- yl)acrylamideIBA
01/2019 |
1 | Biomarkers (Surrogate Marker)IBA
11/2017 |
1 | Hypnotics and Sedatives (Sedatives)IBA
01/2016 |
1 | Antipsychotic Agents (Antipsychotics)IBA
01/2016 |
1 | Platelet Activating FactorIBA
10/2015 |
1 | WEB 2086 (apafant)IBA
10/2015 |
1 | Cyclooxygenase 1IBA
10/2015 |
1 | Hydroxyethyl Starch Derivatives (Pentastarch)FDA Link
09/2014 |
1 | SR 144528IBA
05/2011 |
1 | RimonabantIBA
05/2011 |
1 | CB2 Cannabinoid ReceptorIBA
05/2011 |
1 | CB1 Cannabinoid Receptor (CB1 Receptor)IBA
05/2011 |
1 | 3- (4- chlorophenyl)- N- methyl- N'- ((4- chlorophenyl)sulfonyl)- 4- phenyl- 4,5- dihydro- 1H- pyrazole- 1- carboxamidineIBA
05/2011 |
1 | Prostaglandins DIBA
06/2010 |
1 | Hormones (Hormone)IBA
06/2010 |
1 | CorticosteroneIBA
06/2010 |
1 | Interleukin-6 (Interleukin 6)IBA
06/2009 |
1 | NicotineFDA Link
10/2008 |
1 | N- (7- hydroxy- 5,6,7,8- tetrahydronaphthalen- 1- yl)- 3- (2- (piperidin- 1- yl)- 6- (trifluoromethyl)pyridin- 3- yl)acrylamideIBA
07/2007 |
1 | Dimenhydrinate (DMH)FDA LinkGeneric
12/2006 |
1 | Biological ProductsIBA
10/2006 |
1 | Toll-Like Receptor 4IBA
05/2006 |
1 | IsoenzymesIBA
11/2005 |
1 | NeuropeptidesIBA
09/2005 |
1 | Peptide Hormones (Polypeptide Hormones)IBA
09/2005 |
1 | Prostaglandin E Receptors (Prostaglandin E Receptor)IBA
09/2005 |
1 | AntibodiesIBA
09/2005 |
1 | N- (2- (4- (2- methoxyphenyl)- 1- piperazinyl)ethyl)- N- (2- pyridinyl)cyclohexanecarboxamideIBA
05/2005 |
1 | SB 269970IBA
05/2005 |
1 | Serotonin ReceptorsIBA
05/2005 |